Cytotoxicity of a novel fibroblast growth factor receptor targeted immunotoxin on a human ovarian teratocarcinoma cell line

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 4, 2006, Pages 321-332

  Zhang, Huajie ^a,b   Zhang, Shumin ^b   Zhuang, Hui ^a   Lu, Fengmin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Basic fibroblast growth factor; Diphtheria toxin; Fibroblast growth factor receptor; Immunofluorescence; Immunotoxin

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; DIPHTHERIA ANTIBODY; DIPHTHERIA TOXIN; FIBROBLAST GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TERATOCARCINOMA;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; DIPHTHERIA TOXIN; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOTOXINS; OVARIAN NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TERATOCARCINOMA;

EID: 33750610770     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.321     Document Type: Article

References (24)

1. FitzGerald DJ, Kreitman RJ, Wilson W, et al. Recombinant immunotoxins for treating cancer. Int J Med Microbiol 2004;293:577.
2. Choe S, Bennett MJ, Fujii G, et al. The crystal structure of diphtheria toxin. Nature 1992;357:216.
3. Yamaizumi M, Mekada E, Uchida T, et al. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978;15:245.
4. Frankel AE, Powell BL, Hall PD, et al. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002;8:1004.
5. Cohen KA, Liu TF, Cline JM, et al. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother 2005;54:799.
6. Piascik P. FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc (Wash) 1999;39:571.
7. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000;32:263.
8. Dickson C, Spencer-Dene B, Dillon C, et al. Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors. Breast Cancer Res 2000;2:191.
9. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709.
10. Ozen M, Medrano EE, Ittmann M. Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor. Melanoma Res 2004;14:13.
11. Cronauer MV, Schulz WA, Seifert HH, et al. Fibroblast growth factors and their receptors in urological cancers: Basic research and clinical implications. Eur Urol 2003;43:309.
12. Kuhn H, Kopff C, Konrad J, et al. Influence of basic fibroblast growth factor on the proliferation of non-small-cell lung cancer cell lines. Lung Cancer 2004;44:167.
13. Auguste P, Gursel DB, Lemiere S, et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 2001;61:1717.
14. Baguma-Nibasheka M, Li AW, Osman MS, et al. Coexpression and regulation of the FGF-2 and FGF antisense genes in leukemic cells. Leuk Res 2005;29:423.
15. Beitz JG, Davol P, Clark JW, et al. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo. Cancer Res 1992;52:227.
16. Lappi DA, Maher PA, Martineau D, et al. The basic fibroblast growth factor-saporin mitotoxin acts through the basic fibroblast growth factor receptor. J Cell Physiol 1991;147:17.
17. Davol PA, Frackelton AR. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance. Prostate 1999;40:178.
18. Frankel AE, Ramage J, Kiser M, et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 2000;13:575.
19. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002;8:17.
20. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165.
21. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159.
22. Schmidt A, Mockel B, Eck J, et al. Cytotoxic activity of recombinant bFGF-rViscumin fusion proteins. Biochem Biophys Res Commun 2000;277:499.
23. Liu TF, Urieto JO, Moore JE, et al. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol 2004;32:277.
24. Jeffers M, LaRochelle WJ, Lichenstein HS. Fibroblast growth factors in cancer: Therapeutic possibilities. Expert Opin Ther Targets 2002;6:1.